CSBRChampions Oncology, Inc.
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implant…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress. | ||
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue. | ||
 Champions Oncology Q4 Earnings Call Highlights Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house. For the fourth quar | ||
 CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in. | ||
 2 Microcaps With Gross Margin Catalysts CSBR and CEPL have levers in place for Gross Margin improvement. | ||
 Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing. | ||